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Efficacy and safety of a single 
switch from etanercept originator 
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of inflammatory arthritis
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AntiTNF-α biosimilars are broadly available for the treatment of inflammatory arthritis. There are a lot 
of data concerning the maintenance of clinical efficacy after switching from originators to biosimilars; 
therefore, such a transition is increasingly encouraged both in the US and Europe. However, there 
are reports about flares and adverse events (AE) as a non-medical switch remains controversial due 
to ethical and clinical implications (efficacy, safety, tolerability). The aim of our work was to evaluate 
the disease activity trend after switching from etanercept originator (oETA-Enbrel) to its biosimilar 
(bETA-SP4/Benepali) in a cohort of patients in Turin, Piedmont, Italy. In this area, the switch to 
biosimilars is stalwartly encouraged. We switched 87 patients who were in a clinical state of stability 
from oETA to bETA: 48 patients were affected by Rheumatoid Arthritis (RA),26 by Psoriatic Arthritis 
(PsA) and 13 by Ankylosing Spondylitis (AS).We evaluated VAS-pain, Global-Health, CRP, number 
of swollen and tender joints, Disease Activity Score on 28 joints (DAS28) for RA, Disease Activity in 
Psoriatic Arthritis (DAPSA) for PsA, Health Assessment Questionnaire (HAQ) and Health Assessment 
Questionnaire for the spondyloarthropathies (HAQ-S),Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) for AS patients. 11/85 patients (12.6%) stopped treatment after switching to 
biosimilar etanercept. No difference was found between oETA and bETA in terms of efficacy. However, 
some arthritis flare and AE were reported. Our data regarding maintenance of efficacy and percentage 
of discontinuation were in line with the existing literature.
Biologics are target-specific, highly effective drugs approved for many pathologic conditions such as inflam-
matory arthritis, psoriasis, Crohn disease, uveitis, osteoporosis, cancer, HIV, multiple sclerosis and others. In 
particular, over the last 20 years many advances allowed drugs to actually modify the natural history of rheumatic 
diseases such as Rheumatoid Arthritis, SpondyloArthritis (including Ankylosing Spondylitis), Psoriatic Arthritis, 
Reactive Arthritis, and more recently Systemic Lupus Erythematosus, thanks to their effectiveness in reducing 
disease activity, joint pain, swelling and damage progression. The high cost of Biological Disease Modifying Anti-
Rheumatic Drugs (bDMARDs) in the world is the main factor limiting its prescription as a first line of therapy 
despite the best efficacy and tolerability.
Despite their cost, the three main anti-TNF alpha originators (Humira, Enbrel and Remicade) were amongst 
the top 20 drugs of the world ranking (which accounted for the total global prescription drug market in the 
last years); the annual growth for Humira in 2016 (the first product of the ranking) was 15%, accounting for a 
$16-billion-sale worldwide, which could also be due to its numerous  indications1–8.
Biologics are derived from living cells crossing a complex biotechnological process. The intrinsic nature of 
these proteins makes it almost impossible to replicate an exact copy (generic) of a biological drug; therefore, 
biosimilars are products similar to the original drug in the active substance, but not identical for differences in 
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its manufacturing process, including methods used to purify and stabilize cellular lines, which influence post-
translational modifications of the proteins (such as glycosylation, etc.)9–11.
To date, the patents for 3 anti TNF-alpha (Remicade/Infliximab, Enbrel/Etanercept, Humira/Adalimumab) 
and one anti B-cells (Mabthera/Rituximab) have expired, thus allowing many biosimilars to be available in the 
world for the treatment of inflammatory joint diseases.
Several randomized, double-blind, controlled clinical trials versus placebo demonstrated the efficacy and 
safety of the switch from biologic originators to the biosimilar of infliximab, etanercept and adalimumab as many 
experiences from trials and real world data are  available12–20, thus having been approved for the same indications 
by FDA (including extrapolated suggestions as well)21.
However, despite the considerable saving, such shifts to biosimilar drugs are still being debated, principally 
over their ethical implications. Since the drugs are similar but not identical, the main issues are related to the 
adverse events and the lack of efficacy, which cannot be excluded. This also implies that biosimilars could 
theoretically work better than originators, but the variability in effectiveness for a single patient remains an 
unpredictable datum before effecting the switch.
Despite the fact that extrapolation of indications are debated (especially for the treatment of inflammatory 
bowel diseases since the mechanisms of action might differ from  indications22), the use of biosimilars appears 
to be regulated worldwide by local guidelines if safety and effectiveness are demonstrated in clinical trials for 
at least one indication. Moreover, data concerning immunogenicity, in at least one clinical trial comparing the 
development of anti-drug antibodies in patients previously exposed to the originator, are required by regulatory 
agencies before the approval of the  biosimilar11,23–27.
A small survey conducted in the UK showed an agreement regarding the switch if the treatment "works as 
well as my existing" (40.4%), and 27.3% hoped “that someone who couldn’t otherwise get on to biologic treat-
ment would benefit”28.
Other data showed that the cost saved by switching patients to biosimilars could enable more efficient alloca-
tions of health system resources thus improving patient care. The availability of biosimilars is an opportunity 
to reduce the price of biological therapies that is the main (and sometimes the only) limiting factor in many 
countries, as demonstrated in several  studies29–33 such elements could allow an early access to biological treat-
ments for the patients.
Moreover, the switch is an incentive for the originator pharmaceutical companies not only in reducing prices 
but also to invest in researching and developing new  drugs21,34.
The price of biosimilars is 15–75% lower than the originator; since the intrinsic properties of biosimilar drugs 
(that are not generic drugs but bioequivalent), the interchangeability is a medical decision in almost all countries 
in Western Europe and in the USA. Therefore, this shift is not to be made by pharmacists or by others in order 
to prevent an automatic  substitution10,35.
In literature, several studies and real-world data analysed the short-term impact of the switch from the anti-
TNF originator to its biosimilar suggesting that there is a good maintenance of efficacy and safety; however, there 
are many reports of discontinuation due both lack of efficacy or adverse events. The percentage of interruption 
varies between 4 and 18%17,19,36–46. A Dutch study on 192 patients showed the highest percentage of discontinu-
ation (24%); a sub-analysis of its data verified that the interruption was mainly related to subjective features such 
as tender joints and patient global assessment rather than objective variables. This phenomenon could be due to 
a nocebo  effect43,47 and would require further investigations.
Besides, more recent data from the extension of observation in DANBIO registry confirmed that a certain 
percentage of switches failed due to patients factors rather than elements related to drug  effects48.
However, a critical review emphasized the unbalanced cohort and results, asserting that, as of today, there 
is no study that properly follows FDA guidelines which state that randomised double-blind trials should be 
included in order to ensure: (a) the homogeneity of treatment groups and control bias; (b) an adequate control 
with measurement of different outcomes; (c) a proper statistical powering and an appropriate statistical analysis 
with a well-established evaluation of immunogenicity-related outcomes; (d) an adequate follow-up and assess-
ments of individual patient-level outcomes to support the switch  definitively49,50.
Reasons to switch, regional guidelines and aim. In Italy, the Italian competent authority for drugs 
(AIFA-Agenzia Italiana del Farmaco) published a position papers in 2018 about biosimilars and switching. 
Although AIFA leaves the final decision to the rheumatologist, it also encourages physicians to strongly consider 
literature data about the safety and efficacy of the switch, reminding the physicians of their role and responsibil-
ity in the economic sustainability of the health  system51.
In Italy, biological drugs are fully refunded by the health system. After the authorization of the EMA, AIFA 
issues a decree in order to establish the class and the price of the drug; consequently, the marketing authorisation 
is granted. As soon as this decree is issued, each Italian region inductees an auction for the award of a public 
contract between the different producers; the winner of this auction is then permitted to sell their drug in the 
aforementioned region.
In Piedmont, SB4/Benepali won the auction vs Enbrel in 2017 with a significant price difference.
In our Region, after the AIFA approval for the reimbursement, a commission including members of the 
Regional Pharmaceutical Service and rheumatologists was established in order to produce a regional guidance 
on prescribing drugs for naïve patients and in case of switch. The prescription of biosimilars is highly recom-
mended for naïve patients that require a specific target therapy, whilst the switch from originators to biosimilars 
is encouraged for all the patients treated with the originator; however, some peculiar exceptions are established: 
patients with history of allergy and/or particularly hypersensitive skin, off-label prescriptions, psychological 
reasons, active disease that requires a different treatment in the short term, paediatric patients,  pregnancy52,53.
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The regional recommendations refer exclusively to Etanercept and do not preclude in any way the possibility 
of prescribing the most suitable bDMARD or tsDMARD for the individual patient.
The aim of this work is to evaluate the disease activity trend after switching from etanercept originator Enbrel 
(oETA) to its biosimilar SB4/Benepali (bETA) in a population admitted to Città della Scienza e della Salute 
Hospital in Turin, Piedmont, Italy.
Considering that no changes in clinical outcomes were expected, and according to Regional recommenda-
tions, we properly discussed about these elements with every patient. In addition, the informed consent was bind-
ing in the physician’s final choice as the shared decision between rheumatologists and patients was  mandatory54,55.
Materials and methods
We selected patients with clinical diagnosis of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Anky-
losing Spondylitis (AS) who were admitted to the Rheumatology Unit of the University Hospital of Turin, Italy. 
The patients had been treated with oETA  Enbrel® and switched to bETA  Benepali®. As suggested by a Regional 
document, patients off-label, pregnancy and paediatric, patients with history of allergy, patients not in remis-
sion nor in low disease activity, patients with psychological reasons that forbid a change were excluded. As per 
EULAR  guidelines54, we also excluded patients that refused the switch. At the time of the switch, every patient 
was informed about biosimilar properties, literature data and the possibility to return to originator if necessary. 
Almost all patients accepted the switch.
Sample analysis was stratified by age, sex, duration of disease and concomitant therapy. The disease activity 
was evaluated during the year before the introduction of the bETA, and then the trend of the disease activity 
was evaluated in the following 12 months during oETA treatment. Patients that stopped therapy for any reason 
has been evaluated only until the bETA interruption. It was also examined whether some baseline characteris-
tics, such as the duration of treatment with oETA, concomitant therapy (conventional synthetic DMARDs and 
glucocorticoids) and disease activity, could influence the response to biosimilars.
Statistical analysis was performed using SPSS software (version 17.0, Windows 10 Pro build 1803) and MINI-
TAB (version 14.0, Windows 10 Pro build 1803). Descriptive statistics will be provided for the clinical and 
laboratory demographic characteristics of the cases. In order to evaluate the presence of statistically significant 
differences between the parameters considered, the χ2 test for parametric variables was used. The comparison 
between groups was performed using the Kruskal–Wallis test and the U-Mann–Whitney test. All the performed 
tests were bilateral and the level of significance was set at 5% (with a 95% confidence interval).
Multivariable analysis with logistic regression was performed in order to analyze the association of interrup-
tion therapy with disease activity, concomitant therapy and oETN duration (age, gender and disease duration 
were already normalized at the beginning).
Results
87/107 patients were included (37 male, 50 female) with a median age of 63.0 years old (IQ range 52.2–83.0); the 
patients were divided by pathology (RA, PsA and AS) while analyzing BMI, ACPA and RF positivity, treatment 
lines, duration of disease, duration of therapy with oETA and concomitant therapies (csDMARDs) (see Table 1). 
Patients treated with csDMARDs took Methotrexate in 96% of cases, with a dose between 10 and 15 mg per week. 
The comparisons of the progress of disease activity were evaluated for the different pathologies (RA, PsA and AS) 
with their respective clinimetric indices (DAS28, DAPSA, BASDAI, see Table 2). Data analysis showed there are 
no significant differences in clinimetric parameters after the switch from originator drugs to biosimilars. 11/85 
patients (12.6%) stopped the treatment after switch to biosimilar drugs (bETA) due to lack of efficacy (LOE), 
subjective features (SF) and adverse event (AE); amongst these patients, 5 were affected by RA (3 LOE, 1 SF, 1 
AE), 5 patients were affected by PsA (3 LOE, 1 SF, 1 AE), and 1 patient was affected by AS (1 LOE) (Table 3). The 
AE were not serious: one RA patient showed psoriasis whilst the second one experimented cutaneous rash and 
diffuse itch. Furthermore, a univariate analysis was performed in order to verify a possible correlation between 
the interruption of the therapy with bETA and the disease activity at the onset (RA p: 0.231; PsA p: 0.545; AS p: 
Table 1.  Patient characteristics at baseline. All RA patients has been screened for ACPA and RF while all 
AS patients has been screened for HLA-B27. RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing 
spondylitis, Anti-Citrullinated Protein Antibodies; rheumatoid factor; oETA etanercept originator, csDMARD 
conventional synthetic disease modifying anti-rheumatic drug, BMI body mass index, M* median, IQ inter-
quartile range, M male, F female, yy years.
Pt (n)
Age (M*, IQ; 
yy) Sex (n M/F)
BMI (M*, IQ; 


















(N = 32/48) – 2 (2–7) 16 (10–38) 7 (3–16) 72,9
PsA 26 63 (57–78) 14/12 26.8 (26.2–28.7) – – – 2 (2–3) 15 (13–28) 7 (3–15) 77,7
AS 13 50 (47–67) 11/2 26.8 (24.8–34.7) – –
69.2 
(N = 9/13) 3 (2–5) 13 (10–45) 6 (2–12) 15,3
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0.823), the concomitant therapy (RA p: 0.555; PsA p: 0.623; AS p: 0.213) and the duration of oETA treatment 
(RA p: 0.426; PsA p: 0.676; AS p: 0.522).
Moreover, we performed the multivariable analysis with logistic regression to verify a possible correlation 
between the interruption of therapy with bETA, confounders and exposure variables (Table 4).
Discussion
Biosimilars drugs are similar to the originator in terms of quality, safety and effectiveness but there are many 
open questions about ethical implications.
The main concerns are those regarding the switch from the originator to its biosimilar product; the main 
doubts cover non-medical substitutions which could be performed for situations not related to drug’s efficacy 
nor tolerability nor other medical  reasons10,56.
The European Medical Agency (EMA) leaves the authority about interchangeability or substitution to each 
national agency.
Despite the lack of European guidelines, there is an ever-growing practical experience that demonstrates the 
safety and clinical effectiveness of biosimilars, as well as the savings generated from their introduction in clinical 
 practice39,57–59. Therefore, further expensive trials could be avoided to demonstrate an already existing knowledge.
A large difference exists between Western Europe and Eastern Europe. In the latter, access to expensive drugs 
is limited so the automatic substitution is in some cases allowed, and in many other cases regulated by the  law60.
The Italian competent authority for drugs (AIFA-Agenzia Italiana del Farmaco) published two position papers 
about biosimilars and switching. The aim of the documents was to provide health professionals and patients clear 
and validated information about biosimilars, including the role of biosimilars in the economic sustainability 
of the National Health Service. Even if the final decision about the switch is entrusted to the physician (after a 
Table 2.  Correlation between disease activity and drug therapy (oETA and bETA) before switch and after 
switch, during 6 and 12 months of follow-up. RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing 
spondylitis, DAS28 Disease Activity Score 28, DAPSA Disease Activity in Psoriatic Arthritis, BASDAI Bath 























RA (48 pts) 
DAS28 2.5 (1.8–4.8) 2.5 (1.9–4.7) 2.40 (1.8–7.8) 2.84 (1.8–4.7) 0,740 0,545 0,793 0,742 0,405 0,443
PsA (26 pts) 
DAPSA 10.0 (6.0–31.0) 7.0 (5.0–24.0)
10.5 
(4.0–46.0) 14.9 (6.4–40.8) 0,461 0,506 0,598 1,000 0,205 0,231
AS (13 pts) 
BASDAI 1.7 (1.3–9.0) 2.0 (1.0–7.5) 2.55 (1.0–8.6) 1.75 (1.0–5.,6) 0,697 0,646 0,596 0,901 0,750 0,525
Table 3.  Patients that stopped bETA for any reason. PTS patients, DGN diagnosis, DIS DUR disease duration, 
LoE lack of efficacy, AE adverse event, SF subjective features, yy years, mm months, bDMARD biologic disease-
modifying antirheumatic drug, tsDMARD targeted synthetic disease-modifying antirheumatic drug.
PTS Sex Age DGN DIS DUR (yy) oETA (mm) bETA (mm) LoE AE SF Measures taken
Outcome after 
interruption
1 F 68 RA 10 26 4 √ – – Swap to a tsDMARD Clinical improvement
2 F 58 RA 21 34 8 √ – – Swap to an other bDMARD
Partially improve-
ment
3 F 85 RA 22 102 6 √ – – Swap to an other bDMARD Clinical improvement
4 M 69 RA 14 92 7 – Psoriasis (new onset) – Switch back to originator Resolved
5 F 63 RA 16 78 6 – – Arthralgia worsening Switch back to originator Resolved
6 F 66 PsA 4 26 8 √ – –
Swich to an other 




7 F 71 PsA 18 186 6 √ – – Swich to an other bDMARD
Partially improve-
ment
8 F 70 PsA 17 52 7 √ – – Swich to an other bDMARD Clinical improvement
9 F 74 PsA 10 89 1 – Cutaneous rash – Switch back to originator Resolved
10 F 75 PsA 10 45 4 – – Arthralgia worsening Switch back to originator Resolved
11 M 58 AS 13 84 4 √ – – Switch back to originator Resolved
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proper informed consent given by patients) AIFA sustains the interchangeability of biosimilars and emphasizes 
the physician role in economic sustainability of the health  system52.
The analysis of our real-life data in those patients who agreed to switch, confirms what has already emerged 
from clinical trials and real-world data in the literature. In particular, there were no statistically significant differ-
ences in disease activity after the switch to bETA and during the follow up (1 year after the switch). Furthermore, 
no correlations emerged between the interruption of treatment with bETA and the variables analysed. The adverse 
events were not serious. Amongst real-life data  reports61–67, we collected data for up to 12 months of follow-up. 
However, this descriptive study has some limitations since it includes no data about pharmacokinetics or evalu-
ation of anti-drug antibodies, from neither the originator nor the biosimilar. Finally, the nocebo effect was not 
investigated with psychometric measures.
In addition to this, 20 patients were excluded (21.4% of the sample); despite this element may seem to limit 
the study, it should be taken into consideration that 12 of these patients were carrying out therapies as per off 
label dose reductions (thus not being comparable with the rest), whilst 4 had psychological reasons (which are 
likely to be comprised inside the Nocebo effect) and 4 of them were paediatric patients. So, it can be concluded 
that there is an equal balance of negative and positive aspects that make this data loss less significant.
In conclusion, in our population, no difference has been observed with regard to efficacy and safety after 
the switch from originator to biosimilar, and no predictors of non-response to switch therapy are currently 
highlighted. In our opinion, the switch could be considered safe. The physician–patient cooperation play a key 
role for a successful switch; therefore, it is critical to ensure that patients are informed about all the relevant 
information related to the switch as well as the respect for patients decisions and to make a strict follow-up to 
check any AE immediately.
It is also fundamental to share clinical reports to improve real life data.
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